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ARID1A is frequently mutated in ovarian clear cell
carcinoma (OCCC) and often co-exists with acti-
vating mutations of PIK3CA. Although induction
of pro-inflammatory cytokines has been observed
in this cancer, the mechanism by which the two
mutations synergistically activate cytokine genes
remains elusive. Here, we established an in vitro
model of OCCC by introducing ARID1A knockdown
and mutant PIK3CA into a normal human ovarian
epithelial cell line, resulting in cell transformation
and cytokine gene induction. We demonstrate that
loss of ARID1A impairs the recruitment of the
Sin3A-HDAC complex, while the PIK3CA mutation
releases RelA from IkB, leading to cytokine gene
activation. We show that an NF-kB inhibitor partly
attenuates the proliferation of OCCC and improves
the efficacy of carboplatin both in cell culture and
in a mouse model. Our study thus reveals the mech-
anistic link between ARID1A/PIK3CA mutations and
cytokine gene induction in OCCC and suggests that
NF-kB inhibition could be a potential therapeutic
option.
INTRODUCTION
Ovarian clear cell carcinoma (OCCC) constitutes 10%–15%
of all ovarian cancers (Jones et al., 2010). OCCC is regarded
as one of the most aggressive cancers because it is generally
refractory to conventional chemotherapies such as Taxol
or cisplatin (Bast et al., 2009). Genome sequencing of
OCCC patient samples has revealed highly recurrent loss-of-
function mutations in ARID1A (Jones et al., 2010; Wiegand
et al., 2010), a core subunit of the SWItch (SWI)/sucrose
non-fermentable (SNF) ATP-dependent chromatin-remodeling
complex (Wilson and Roberts, 2011). Interestingly, ARID1A
mutations often co-exist with activating mutations of PIK3CA,Cell Re
This is an open access article under the CC BY-Nsuggesting that they may cooperate in driving OCCC devel-
opment (Samartzis et al., 2013; Yamamoto et al., 2012).
Indeed, Arid1a knockout/Pik3ca H1047R transgenic mice
develop spontaneous OCCC, indicating that the two muta-
tions are sufficient in initiating OCCC (Chandler et al., 2015).
Previous studies have revealed that OCCC is associated
with increased expression of pro-inflammatory cytokines
in both human and mouse models (Chandler et al., 2015; Ya-
maguchi et al., 2010). Consistently, inhibition of interleukin-6
(IL-6) in cell culture reduced proliferation of OCCC cells
(Chandler et al., 2015; Kumar and Ward, 2014), suggesting
induction of pro-inflammatory cytokine might contribute to
OCCC tumorigenesis. However, how the two mutations coop-
erate to induce pro-inflammatory cytokines is not clear.
Understanding the molecular mechanism underlying this pro-
cess could help develop strategies overcoming dysregulation
of cytokines, which can serve as a potential treatment for
OCCC.
Studying tumorigenesis mechanism in existing cancer cell
lines is confounded by the different mutations acquired during
their derivation and maintenance. To circumvent this problem,
we utilized hTERT-immortalized normal human ovarian epithe-
lial cell lines (Liu et al., 2004). By introducing ARID1A small
hairpin RNA (shRNA) and PIK3CA mutations to normal human
ovarian epithelial cells, we created an in vitro OCCC model. Us-
ing this model, we identified RelA nuclear factor kB (NF-kB)
transcription factor to be a major factor driving cytokine in-
duction. Mechanistically, we demonstrate that PIK3CA acts
through the AKT-IKK2 pathway to release RelA from inhibitor
of kappa B (IkB). In addition, disruption of ARID1A impairs
the recruitment of the Sin3A histone deacetylase (HDAC)
repressor complex to cytokine genes, leading to their derepres-
sion. Importantly, inhibition of NF-kB by a chemical inhibitor
attenuated the in vitro and in vivo growth of double-mutant
cells and improved the efficacy of carboplatin, a clinically
used cisplatin derivative. Our study thus not only reveals how
mutations of a signaling molecule and an epigenetic factor
can cooperate to drive tumorigenesis but also raises the possi-
bility of inhibiting the NF-kB pathway as a potential treatment
for OCCC.ports 17, 275–288, September 27, 2016 ª 2016 The Author(s). 275
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. ARID1A Depletion and PIK3CA Activation Transform Normal Human Ovarian Epithelial Cells
(A) Introduction of double mutations into the T80 cell line. T80 cells were transduced with retroviruses expressing an ARID1A shRNA and the indicated PIK3CA
alleles. After selection, the transduced cells were analyzed by western blotting.
(B) Phase contrast images of established cell lines. Scale bar, 50 mm.
(C) Growth curve of the established T80 cell lines expressing single or double mutant. 5 3 105 of the indicated cells were plated on six-well plates and counted
every 2 days (n = 3). Error bars indicate SEM. Statistical analysis comparing AM or AE cells with control cells was performed on day 14.
(D) Soft agar assay of the established T80 cell lines expressing single or double mutant. Representative images of soft agar colonies. Scale bar, 10 mm.
(E) Colony numbers per 1.63 field were counted (n = 3). Error bars indicate SEM.
(legend continued on next page)
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RESULTS
ARID1A Depletion and PIK3CA Mutations Transform
Normal Human Ovarian Epithelial Cells
To generate an in vitro model for the study of OCCC containing
loss-of-ARID1A-function and gain-of-PIK3CA-function muta-
tions, we introduced single or double mutations into the immor-
talized normal human ovarian epithelial cell line T80 (Liu et al.,
2004) by depleting ARID1A using a shRNA and/or expressing
active PIK3CA, respectively (Figure 1A). For PIK3CA, we used
either PIK3CA E545K or myristoylation-signal-attached PIK3CA
(Myr-PIK3CA). PIK3CA E545K is a naturally occurring mutant
PIK3CA found in cancer patients that has increased enzymatic
activity (Samuels et al., 2005), while Myr-PIK3CA is forcibly
recruited to membrane and is constitutively active (Bitler et al.,
2015). Although cells expressing ARID1A shRNA or active
PIK3CA alone exhibit cell morphology similar to that of control,
cells with both (hereafter AE for ARID1A shRNA and E545K
and AM for ARID1A shRNA and Myr-PIK3CA) have strikingly
different morphology, with smaller size and disrupted organiza-
tion (Figure 1B). Although T80 (AE) and T80 (AM) cells exhibited
an initial growth rate similar to that of control T80 cells or cells
with a single mutation, they appeared to have lost cell contact in-
hibition growth, as they kept growing by piling up on each other
(Figure 1C). To ascertain that these observations are not due to a
peculiar property of the T80 cell line, we performed similar exper-
iments in T29, another independently established normal human
ovarian epithelial cell line (Liu et al., 2004). Results shown in
Figure S1 indicate that introduction of the double mutations
also caused a morphological change as well as loss of contact
inhibition of growth (Figures S1B and S1C).
Next, we examined the ability of T80 cells harboring the double
mutations to grow in an anchorage-independent manner. To this
end, soft agar assay was performed using cells with single or
double mutations. Results shown in Figures 1D and 1E indicated
that cells with active PIK3CA displayed a weak ability to grow in
soft agar, which was drastically enhanced when combined with
ARID1A depletion. Importantly, both PIK3CA mutations ex-
hibited a similar result. To evaluate the tumorigenecity of the cells
harboring the two mutations, T80 (AM) cells were subcutane-
ously injected into nude mice. 2 weeks after the injection,
palpable tumors were observed in all mice tested (five out of
five), which is in contrast with the mice injected with the same
number of control T80 cells (Figure 1F). Collectively, the above
results suggest that ARID1A depletion in combination with
PIK3CA activation is sufficient to transform normal human
ovarian epithelial cells.
ARID1A Depletion and PIK3CA Activation Induce Pro-
inflammatory Cytokine Expression
To gain insight into the molecular mechanism of how combined
loss of ARID1A and gain of PIK3CA function contributes to trans-
formation of human ovarian epithelial cells, we performed tran-(F) T80 cell line harboring the double mutant can form tumors in nude mice. Six-w
T80 or T80 (AM) cells (two independent experiments with five mice total in each
curve). Mice were imaged at the time of sacrifice (right). Scale bar, 5 cm.
*p < 0.05; **p < 0.01. See also Figure S1.scriptome analyses by RNA sequencing (RNA-seq). To this end,
T80 and T29 cells, as well as their derivatives harboring single or
double mutations, were used for RNA-seq analysis. Comparison
of their transcriptomes revealed 59 genes uniquely upregulated
in the cells harboring double mutations (fold change [FC]R 2 in
both T29 [AM] and T80 [AM] cells) (Figure 2A; Table S1). To
examine if these upregulated genes are relevant to human
OCCC, we performed a gene set enrichment analysis using the
identified 59 genes. By analyzing an available OCCC patient
gene expression dataset GSE6008 (Hendrix et al., 2006), we
confirmed that the 59 genes were indeed enriched in the upregu-
lated gene groups in OCCC patient samples (Figure 2B), support-
ing the relevance of the upregulation of these genes to human
OCCC. Gene Ontology (GO) analysis revealed cytokine/chemo-
kine activity as the most enriched GO term (Figure S2A). Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis
also revealed cytokine signaling as the most enriched pathway
(Figure S2B). Among the 59 genes identified, 14 belong to the
pro-inflammatory cytokines, including IL-1A, IL-1B, IL-6, IL-8,
CXCL1, and CXCL3 (Table S1). To confirm the RNA-seq result,
we performed qRT-PCR on a subset of cytokine genes. Results
shown in Figure 2C indicated that either ARID1A depletion or
PIK3CA activation alone only slightly upregulated cytokine gene
expression.However, thecombinedmutations resulted ina robust
activation. Similar resultswere also obtained in cells harboring the
AE mutations (Figure S2C). In contrast to the upregulated genes,
no enrichment of any GO term or pathway was identified in the
downregulatedgenes, suggesting that upregulation of these cyto-
kinesmayunderlie themolecular functionof thedoublemutations.
The finding that double mutations result in upregulation of pro-
inflammatory cytokines is intriguing. First, upregulation of certain
cytokines has been previously observed in a mouse OCCC
model and human OCCC patients (Chandler et al., 2015; Yama-
guchi et al., 2010), suggesting its clinical relevance. Second,
several of these cytokines, including IL-6, IL-8, and CXCL1,
have been previously implicated in promoting cell proliferation,
survival, chemoresistance, metastasis, and cancer stem cell
expansion (Acharyya et al., 2012; Grivennikov et al., 2009; Ilio-
poulos et al., 2009; Schafer and Brugge, 2007; Waugh and Wil-
son, 2008). Thus, induction of these oncogenic cytokines may
contribute to tumorigenesis. Consistent with a previous report
that blocking IL-6 function can reduce proliferation of cancer
cells harboring ARID1A/PIK3CA mutations (Chandler et al.,
2015), neutralizing antibody against IL-6 was able to slow
down proliferation of T80 (AM) cells, but not control T80 cells
(Figure 2D). Collectively, T80 (AM) cells offer an in vitro
experimental model for understanding the molecular basis of
ARID1A/PIK3CA-mutation-induced OCCC.
RelA NF-kB Transcription Factor Is a Major Contributing
Factor in Pro-inflammatory Cytokine Activation
Previous studies have established that the signal transducer
and activator of transcription (STAT) and NF-kB transcriptioneek-old female nu/nu mice were subcutaneously injected with 33 105 control
group). Tumor volume was measured every week for each mouse (left growth
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Figure 2. CytokineGenesAreAberrantly Up-
regulated in ARID1A/PIK3CA Mutant Cells
(A) Heatmap of the genes commonly upregulated
in T29 (AM) and T80 (AM) cells compared to all
other cell lines (FCR 2).
(B) Genes identified in (A) are enriched in the up-
regulated genes in OCCC. Genes upregulated in
patient OCCC samples relative to normal tissues
(from GSE6008) were ranked from left to right, and
gene set enrichment on the upregulated genes can
be seen in the top and middle panels.
(C) qRT-PCR verification of the RNA-seq result.
mRNA level of selected cytokines genes were
validated by qRT-PCR, normalized by b-actin
transcripts (n = 3 for all experiments except CXCL1
in T29, of which n = 4). Error bars indicate SEM.
(D) IL-6 antibody can partly block T80 (AM), but not
T80, cell growth. Control T80 or T80 (AM) cells
were incubated with anti-mouse immunoglobulin
G (IgG) or IL-6 neutralizing antibody (2 ng/mL)
(n = 3), and the cell proliferation rate was
measured. Error bars indicate SEM.
*p < 0.05; **p < 0.01. See also Figure S2 and
Table S1.pathways play an important role in cytokine gene induction
(Grivennikov and Karin, 2010). To examine whether the two
pathways are involved in ARID1A/PIK3CA-mutation-caused
cytokine induction, we treated T80 (AM) cells with either a
STAT inhibitor (1 mM ruxotinilib) or an NF-kB inhibitor (1 mM
IKK-IIV) and quantified cytokine expression by qRT-PCR.
While ruxotinilib had no significant effect, IKK-IIV markedly
reduced the expression of cytokine genes (Figure 3A), indi-278 Cell Reports 17, 275–288, September 27, 2016cating that cytokine gene induction in
the double-mutant cell is mainly medi-
ated through the NF-kB pathway. Given
that STAT activation was observed in
both a mouse OCCC model and human
OCCC patients (Chandler et al., 2015;
Yamaguchi et al., 2010), it was surpris-
ing that STAT inhibition did not result
in cytokine gene suppression. Because
STAT can be activated by cytokines
(Grivennikov and Karin, 2010), our re-
sults suggest that STAT activation
observed in OCCC is likely a second-
ary effect of NF-kB-mediated cytokine
induction.
To substantiate the role of NF-kB
in cytokine gene activation in the context
of ARID1A/PIK3CA double mutations,
we performed genetic manipulation.
The NF-kB family transcription factors
include both RelA and RelB that target
overlapping as well as specific genes
(Napetschnig and Wu, 2013; Sun,
2011). To determine whether RelA or
RelB is involved in cytokine gene activa-
tion, we obtained small interfering RNAs(siRNAs) that deplete RelA or RelB, respectively (Figures S3A
and S3B). While RelA knockdown efficiently decreased cyto-
kine gene expression in T80 (AM) cells, knockdown of RelB
had no significant effect (Figures 3B and S3C). RelA and RelB
are differentially regulated by the IKK signalosome, which con-
sists of three core proteins, IKK1 (IKKa), IKK2 (IKKb), and IKKg,
with IKK1 and IKK2 functioning as kinases and IKKg serving as
a regulatory subunit. In response to signals that activate IKK2,
Figure 3. The RelA NF-kB Transcription
Factor Is Required for Cytokine Gene Acti-
vation in ARID1A/PIK3CA Mutant Cells
(A) The NF-kB inhibitor IKK-IIV, but not the STAT
inhibitor ruxotinilib, inhibited cytokine expression
in T80 (AM) cells. T80 (AM) cells were treated with
DMSO, ruxotinilib (1 mM) or IKK-IIV (1 mM) for
3 days. Control cells were treated with DMSO.
Expression of selected cytokines genes was
measured by qRT-PCR, normalized by b-actin
(n = 3). Error bars indicate SEM.
(B) RelA knockdown reduced cytokine gene
expression. Control and T80 (AM) cells were
transfected as indicated and the expression of
selected cytokines genes were analyzed by qRT-
PCR 3 days after transfection (n = 4). Error bars
indicate SEM.
(C)RelA inhibitionbyadominant-negative IkBpartly
reduced cytokine gene expression. T80 (AM) cells
were infected with empty or IkBa-SR expression
retrovirus vector. After selecting with 100 ng/mL
Zeocin for 2 days, surviving cells were analyzed by
qRT-PCR (n = 4). Error bars indicate SEM.
(D) Cytokine genes are direct RelA targets. ChIP
analysis was performed in the indicated cells using
antibodies against rabbit IgG (control) or RelA.
Immunoprecipitated samples were PCR amplified
using primers that amplify the RelA elements of the
indicated genes. The signals were normalized with
input (n = 3). IgG of control cells was set as 1. Error
bars indicate SEM. Statistical analysis comparing
RelA ChIP in AM and control cells is presented.
*p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S3.IKK2 phosphorylates IkB, leading to its degradation, which then
frees RelA from IkB-mediated cytoplasmic sequestration (Mer-
curio et al., 1997; Xia et al., 2014). To confirm RelA-mediated
cytokine induction is part of the IKK signaling, we used a domi-
nant-negative IkBa, IkBa-SR, which carries two serine-to-
alanine mutations in IKK2 target sites and thus can block
IKK2 signaling when overexpressed (Brown et al., 1995). Re-
sults shown in Figure 3C indicate that expression of IkBa-SR
in T80 (AM) cells successfully reduced cytokine gene expres-
sion. We note that IKK-IIV, IkBa-SR, or RelA depletion did not
completely suppress cytokine gene expression to the level of
control cells. This is likely due to the existence of additional fac-
tors contributing to cytokine expression. Nevertheless, our re-Cell Repsults using multiple approaches indicate
that RelA does play a major role in
driving cytokine gene expression in
the ARID1A/PIK3CA double mutant T80
(AM) cells. Importantly, RelA appears
to directly contribute to cytokine gene
upregulation, as chromatin immunopre-
cipitation (ChIP) qPCR analysis demon-
strates that RelA’s occupancy at the
NF-kB binding elements of IL-6, IL-8,
IL-1B, and CXCL1 genes is significantlyincreased in T80 (AM) cells compared to other control cells
(Figure 3D).
The PIK3CA-AKT-IKK2 Pathway Releases RelA from IkB
Wenext attempted to establish a link between PIK3CA activation
and RelA-mediated cytokine gene activation. Previous studies in
Jurkat cells or human fibroblasts have indicated that AKT, the
main downstream target of PIK3CA, can free RelA from IkB by
regulating IKK2 (Kane et al., 1999; Romashkova and Makarov,
1999). To examine whether a similar relationship exists in human
ovarian epithelial cells, we introduced PIK3CA activation (Myr-)
and ARID1A knockdown in T80 cells. While Myr-PIK3CA expres-
sion reduced IkB and increased phospho-IkB levels, ARID1Aorts 17, 275–288, September 27, 2016 279
Figure 4. Active PIK3CA Releases RelA from IkB through the AKT-IKK2 Pathway
(A) PIK3CA leads to IkBphosphorylation.Western blot analysis of total and phosphorylated IkB in T80 cells expressing shARID1A,Myr-PIK3CA, or a combination.
b-actin serves as a loading control.
(B) PIK3CA leads to nuclear localization of RelA. The indicated cells were fractionated to cytoplasm and nucleus and analyzed by western blotting for RelA and
RelB. Lamin B and a-tubulin were used as nuclear and cytoplasmic markers, respectively.
(C) Nuclear localization of RelA in PIK3CA cells. Immune staining of RelA in the indicated cells co-stained with DAPI. Scale bar, 10 mm.
(D) IKK2-CA can replace PIK3CA in mediating IkB phosphorylation. T80 cells were transduced with retroviruses expressing ARID1A shRNA or IKK2-CA or in
combination. Total and phosphorylated IkB levels were analyzed by western blotting.
(E) IKK2-CA causes cytokine gene activation. Cells from (D) were analyzed by qRT-PCR for the indicated cytokine genes, normalized by b-actin transcripts (n = 4).
Error bars indicate SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.knockdown had no effect on IkB status (Figure 4A). Consistently,
Myr-PIK3CA expression increased nuclear amount of RelA, but
not RelB, as judged by western blotting (Figure 4B), which was
further supported by immunostaining (Figure 4C).
To test whether AKT is a downstream effector of ARID1A/
PIK3CA double-mutation-mediated cytokine induction, we
treated T80 (AM) cells with MK-2206, an AKT-specific inhibi-
tor. MK-2206 treatment not only restored IkB levels (Fig-
ure S4A) but also suppressed cytokine induction (Fig-
ure S4B), indicating AKT is an integral component of the280 Cell Reports 17, 275–288, September 27, 2016ARID1A/PIK3CA-mediated cytokine induction pathway. If the
PIK3CA-AKT pathway releases RelA from IkB through IKK2,
then constitutively active IKK2 (IKK2-CA) should be able to
replace PIK3CA. To test this hypothesis, we established cell
lines expressing IKK2-CA with or without ARID1A shRNA (Fig-
ure 4D). We found that cells with both IKK2-CA and ARID1A
shRNA robustly induced cytokine gene expression (Figure 4E).
This result, together with the fact that the IKK inhibitor abol-
ishes cytokine expression (Figure 3A), allowed us to conclude
that the functional effect of PIK3CA mutation in activation of
cytokines is to release RelA from IkB through the AKT-IKK2
pathway.
ARID1A Recruits the Sin3A-HDAC Complex to Cytokine
Genes
We next attempted to understand how loss of ARID1A function
contributes to RelA-mediated cytokine gene induction. Since
ARID1A is a component of the SWI/SNF ATP-dependent remod-
eling factor, we first considered the possibility that loss of
ARID1A might affect chromatin accessibility by RelA, thus
changing RelA-mediated cytokine gene expression. To address
this possibility, we performed DNaseI hypersensitivity site (DHS)
analysis byDNaseI hypersensitive sites sequencing (DNase-seq)
(Neph et al., 2012). Consistent with the known function of the
SWI/SNF complex in facilitating chromatin access, depletion of
ARID1A resulted in loss of 153 (control versus ARID1A shRNA,
FC R 3) and 557 (Myr-PIK3CA versus AM, FC R 3) DHSs,
respectively (Figure S5A). However, neither ARID1A shRNA
alone nor ARID1A/PIK3CA double mutations generated new or
increased DHS signal (FC R 3), including the genomic regions
of the altered cytokine genes (Figure S5B). Thus, increased cyto-
kine expression in T80 (AM) cells is not likely due to increased
RelA accessibility to the cytokine genes. The lack of a significant
effect of loss ARID1 function on the cytokine gene accessibility
by RelA is likely due to the fact that the RelA binding sites are
already accessible in control cells (Figure S5B, red bars).
After ruling out the possibility that ARID1A depletion contrib-
utes to cytokine induction through regulating chromatin accessi-
bility, we explored alternative mechanisms. Although the SWI/
SNF complex is mostly involved in gene activation, it can also
repress transcription by recruiting histone deacetylase com-
plexes (Harikrishnan et al., 2005; Zhang et al., 2000). It is possible
that ARID1A depletion may affect HDAC complex recruitment,
leading to derepression of cytokine gene expression. Before
testing if ARID1A recruits the Sin3A-HDAC complex to the cyto-
kine genes, we first demonstrated that ARID1A does bind to the
promoters of IL-6 and IL-8 genes in T80 cells by ChIP assays
(Figures 5A and 5B). We then asked whether the histone acety-
lation status at the ARID1A binding sites is affected by ARID1A
depletion. ChIP analysis using a pan-H4 acetylation antibody re-
vealed that knockdown of ARID1A in T80 (AM) cells resulted in an
increase in histone acetylation at the IL-6 and IL-8 promoters
(Figure 5C). Consistently, HDAC1 binding to these regions was
lost in response to ARID1A knockdown, but not to PIK3CA acti-
vation (Figure 5D), supporting a role of ARID1A in the recruitment
of HDAC1 to these gene promoters.
To examine whether the enzymatic activity of the recruited
HDAC is involved in suppressing cytokine gene expression, we
tested the effect of the HDAC inhibitor, trichostatin A (TSA).
Remarkably, TSA treatment greatly induced cytokine gene
expression in cells expressing Myr-PIK3CA (Figure 5E) but only
modestly induced cytokine gene expression in control cells, indi-
cating a synergistic effect between HDAC inhibition and PIK3CA
activation in cytokine induction. We further demonstrated that
the HDAC1 involved is part of the Sin3A complex, as depletion
of Sin3A by siRNAs, similar to that of HDAC inhibition, was
able to synergize with Myr-PIK3CA to induce cytokine expres-
sion (Figures 5F and S6). Interestingly, a recent study indicatedthat ARID1A can recruit the Sin3A-HDAC complex to the telome-
rase gene in ovarian cancer (Suryo Rahmanto et al., 2016).
Collectively, these results support the notion that ARID1A re-
cruits the Sin3A-HDAC complex to suppress cytokine gene
expression. Thus, loss of ARID1A can synergize with RelA acti-
vated by PIK3CA.
The Mechanism of Cytokine Gene Activation Is
Conserved in Human OCCC Cells
Having established themechanism of cytokine gene activation in
the T80 cell linemodel, we next askedwhether thismechanism is
also used for cytokine gene activation in patient-derived OCCC
cell lines. To this end, two OCCC cell lines (TOV-21G, which
carries both ARID1A and PIK3CA mutations, and ES-2, which
does not harbor mutation on either ARID1A or PIK3CA) were
used to address the question. Similar to the results obtained
in T80, TOV-21G cells had decreased IkB expression and
increased phospho-IkB expression compared to ES-2 cells (Fig-
ure 6A). Consistently, nuclear RelA expression was higher in
TOV-21G cells compared to that in ES-2 cells, as judged by
both cell fractionation and immune staining (Figures 6B and
6C). Additionally, IKK-IIV effectively decreased cytokine gene
expression in TOV-21G cells, but not in ES-2 cells (Figure 6D).
Furthermore, siRNA-mediated depletion of RelA decreased
cytokine gene expression in TOV-21G cells, but not in ES-2 cells
(Figure 6E). ChIP-qPCR analysis confirmed that RelA binds to
cytokine genes in TOV-21Gcells, but not in ES-2 cells (Figure 6F).
Finally, we analyzed histone acetylation status and HDAC1
recruitment and found that histone acetylation is increased and
HDAC1 recruitment is decreased in TOV-21G cells relative to
that in the ES-2 cells, respectively (Figures 6G and 6H). Collec-
tively, these results demonstrate that the mechanism used for
cytokine induction in T80 (AM) cells is conserved in the human
OCCC TOV-21G cell line.
NF-kB Inhibitor Attenuates Growth of ARID1A and
PIK3CA Mutant Cells and Improves the Efficacy of
Carboplatin
The fact that a PIK3CA activating mutation caused cytokine acti-
vation through RelA raises the possibility that NF-kB inhibitors
could be used as a novel therapy for OCCC with ARID1A and
PIK3CAmutations. Pro-inflammatory cytokines have been previ-
ously implicated in several aspects of tumorigenesis, including
cell proliferation and survival and in conferring resistance to
chemotherapy, especially cisplatin (Acharyya et al., 2012; Gri-
vennikov et al., 2009; Iliopoulos et al., 2009; Schafer and Brugge,
2007). Therefore, we thought that an NF-kB inhibitor may atten-
uate cell proliferation and improve the efficacy of cisplatin
through suppression of cytokine gene activation. The latter effect
is particularly relevant given that OCCC is known to be cisplatin
resistant (Bast et al., 2009). To this end, we first tested the effect
of an NF-kB inhibitor on cell proliferation and found that while the
proliferation rate of control cells or cells with a single mutation
was not affected, growth of T80 (AM) cells was partly attenuated
by the NF-kB inhibitor IKK-IIV (Figure 7A, black and purple
curves). The partial attenuation might be due to either a partial
rescue of cytokine gene expression by IKK-IIV or a limited contri-
bution of cytokines to cell proliferation. Interestingly, when cellsCell Reports 17, 275–288, September 27, 2016 281
Figure 5. ARID1A Suppresses Cytokine Gene Expression by Recruiting the Sin3A-HDAC Complex
(A) Schematic diagrams of the IL-6 and IL-8 gene loci for ChIP analysis. Transcription start sites (TSSs) are indicated by arrows. Filled boxes indicate exons. The
two amplicons at promoter regions are indicated. Scale bar, 0.5 kb.
(B) ARID1A binds to IL-6 and IL-8 promoters. T80 cells were subjected to chromatin immunoprecipitation (ChIP) using an antibody against IgG or ARID1A. The
amplicons are indicated in (A), and the signals are normalized by input (n = 3). Error bars indicate SEM.
(C) ARID1A knockdown results in increased histone acetylation. The indicated T80 cells were subjected to ChIP analysis using an H4 or a pan-acetylated H4
antibody. ChIP sampleswere PCR amplified using the indicated primers. Acetylated H4was normalized byH4. For each amplicon, control cell was set to 1 (n = 4).
Error bars indicate SEM.
(D) Loss of HDAC1 recruitment in ARID1A knockdown T80 cell lines. Indicated T80 cells were subjected to ChIP analysis using antibodies against IgG or HDAC1.
ChIP samples were PCR amplified using indicated primers, normalized by input (n = 3 for all experiments except TSS in IL-8, of which n = 4). IgG in control cells
was set as 1. Error bars indicate SEM.
(E) Histone deacetylase activity is required for suppressing cytokine gene expression. The indicated cells were treated with DMSO or TSA (100 nM) for 2 days and
analyzed by qRT-PCR of selected cytokines, normalized by b-actin (n = 3). Error bars indicate SEM.
(F) Sin3A depletion resulted in derepression of cytokine genes. Control or Myr-PIK3CA T80 cells were transfected with the indicated siRNAs. 3 days after
transfection, cells were analyzed by qRT-PCR (n = 4). Error bars indicate SEM.
*p < 0.05; **p < 0.01. See also Figure S6.
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Figure 6. Mechanism of Cytokine Gene Activation Is Conserved in a Human OCCC Cell Line
(A) The phosphorylation state of IkB in ARID1A/PIK3CA mutant and wild-type OCCC cell lines. ES-2 (wild-type) and TOV-21G (double mutant) cell lysates were
analyzed by western blotting using the indicated antibodies. Arrow points to IkB.
(B) RelA is localized in nucleus in TOV-21G cell. ES-2 and TOV-21G cells were fractionated to the cytoplasm and nucleus and analyzed by western blot with RelA
and RelB antibodies.
(C) Nuclear localization of RelA in TOV-21G cells, and immune staining of RelA in the indicated cells co-stained with DAPI. Scale bar, 10 mm.
(D) The NF-kB inhibitor IKK-IIV suppresses cytokine gene expression in the TOV-21G, but not in the ES-2, OCCC cell line. Cells were treatedwith DMSOor IKK-IIV
(1 mM) for 3 days. Their effect on cytokine gene expression was analyzed by qRT-PCR (n = 3). Error bars indicate SEM.
(E) RelA knockdown suppresses cytokine gene expression in the TOV-21G, but not in the ES-2, OCCC cell line. Cells were transfected as indicated, and the
expression of selected cytokine genes was analyzed by qRT-PCR 3 days after transfection (n = 4). Error bars indicate SEM.
(legend continued on next page)
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were treated with carboplatin, a clinically used derivative of
cisplatin, only T80 (AM) cells showed persistent growth, while
the growth of other cells was effectively arrested (Figure 7A,
green curves). Importantly, when carboplatin was combined
with IKK-IIV, growth of T80 (AM) cells was also arrested (Fig-
ure 7A, red curves). Of note, recombinant IL-6 and IL-8 was
able to rescue this effect (Figure S7), indicating that IL-6 and
IL-8 activation is mainly responsible for the chemoresistant ef-
fect. Consistent with its effect on T80 (AM) cells, IKK-IIV partially
attenuated proliferation of TOV-21G cells, but not that of the
ES-2 cells (Figure 7B, black and purple curves). Importantly,
when combined with carboplatin, IKK-IIV completely arrested
TOV-21G cell proliferation (Figure 7B, red curves).
To examine whether the combined therapy is also effective
in vivo, we transplanted TOV-21G cells into nude mice by sub-
cutaneous injection. When the tumors reached palpable size
(100 mm3), we divided the mice into four groups randomly
and subjected them to the following treatment: saline control,
carboplatin only (30 mg/kg, once per week), IKK-IIV only
(25 mg/kg, twice per week), and carboplatin plus IKK-IIV,
respectively. While single treatments showed partial attenua-
tion of tumor growth, combined treatment completely arrested
tumor growth (Figures 7C and 7D). These results demonstrate
that the NF-kB inhibitor IKK-IIV is able to selectively suppress
proliferation of ARID1A/PIK3CA double-mutant cells and has
the potential to improve the efficacy of carboplatin in OCCC
treatment.
DISCUSSION
Understanding the molecular mechanisms underlying un-
controlled cellular proliferation resulting from cancer initi-
ating mutations is critical for developing effective treatment.
Despite the identification of a large number of epigenetic
factor mutations in various cancers, how these mutations
contribute to tumorigenesis is poorly understood. Here, we
report how a loss-of-function mutation in an epigenetic factor
(ARID1A) synergizes with a gain-of-function mutation in a
signaling factor (PIK3CA) to contribute to tumorigenesis in
OCCC through inducing pro-inflammatory cytokine gene
expression (Figure 7E). Mechanistically, loss of ARID1A re-
leases cytokine genes from Sin3A-HDAC-mediated repres-
sion, while activating mutation of PIK3CA frees RelA from
IkB so that RelA can enter the nucleus to activate cytokine
genes. These mechanistic insights prompted us to test the
therapeutic potential of an NF-kB inhibitor in combination
with carboplatin, which is supported by our data presented
in Figure 7. Our results thus provide the missing mechanistic
link between ARID1A/PIK3CA mutations and cytokine gene
induction.(F) RelA binds at IL-6 and IL-8 promoters in TOV-21G cells. ChIP analysis was pe
normalized to input (n = 4). IgG of control cells was set as 1. Error bars indicate
(G) HDAC1 binding at IL-6 and IL-8 is decreased in TOV-21G cells. ChIP analysis
Error bars indicate SEM.
(H) Histone acetylation at IL-6 and IL-8 promoters is decreased in TOV-21G cells. C
H4 antibody. For each amplicon, the control cell was set to 1 (n = 4). Error bars i
*p < 0.05; **p < 0.01.
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Components of the SWI/SNF complex, including ARID1A, are
frequently mutated in different types of cancers (Kadoch and
Crabtree, 2015). Understanding how these mutations contribute
to oncogenesis is of great importance. Although the DNaseI
accessibility to the cytokine genes is not altered by loss of
ARID1A, the recruitment of the Sin3A-HDAC complex to cyto-
kine genes is impaired by loss of ARID1A. HDAC1 and HDAC2
exist in at least two distinctive protein complexes that include
nucleosome remodeling and deacetylase (NuRD) and Sin3A
(Zhang et al., 1997, 1998). The NuRD complex has established
function in cancer (Lai and Wade, 2011; Wang et al., 2009).
Therefore, HDAC inhibitors have been widely used as anti-
cancer drugs with promising outcomes (Minucci and Pelicci,
2006). In contrast, the role of the Sin3A-HDAC complex in cancer
has been unclear. Interestingly, our results indicate that the
Sin3A-HDAC complex serves as a tumor suppressor in OCCC.
Consistent with the fact that an HDAC inhibitor failed to show
beneficial effects in cisplatin-resistant ovarian cancers in a
phase 2 clinical trial (Mackay et al., 2010), our results suggest
that HDAC inhibitors would not be effective for OCCC and could
even cause unfavorable outcomes.
An unanswered but important remaining question is whether
the chromatin-remodeling function of ARID1A contributes to
OCCC development. It is hard to imagine that recruitment of
the Sin3A-HDAC complex is the sole function of ARID1A contrib-
uting to OCCC. Future studies analyzing the relationship be-
tween transcriptional changes and DNase I sensitivity changes
may reveal additional ARID1A functions. It is likely that the com-
bined effect of chromatin-remodeling-dependent and indepen-
dent functions of ARID1A contribute to oncogenesis in OCCC.
Gain of RelA Activation Drives Aberrant Cytokine Gene
Induction in OCCC
The NF-kB pathway plays a central role in cancer biology
through activating multiple genes involved in cell proliferation,
survival, drug resistance, angiogenesis, and metastasis (Baud
and Karin, 2009; Karin et al., 2004). Thus, NF-kB inhibition has
been reported to increase the efficacy of several anticancer re-
agents (Nakanishi and Toi, 2005). However, the role of NF-kB
in OCCC has been poorly characterized. Our results suggest
that the RelA NF-kB transcription factor has an important role
in OCCC development and progression. Constitutive activation
of NF-kB has been observed in many types of cancers, espe-
cially hematological cancers (Horie, 2013). In these tumors,
NF-kB is usually activated by mutations of genes that directly
regulate NF-kB. Constitutive NF-kB activity is also found in
some solid tumors, where NF-kB is usually activated by in-
flammatory cues (e.g., smoking or intestinal inflammation)rformed using antibodies against rabbit IgG (control) or RelA. The signals were
SEM.
was performed using antibodies against IgG or HDAC1 and processed as (F).
hIP analysis was performed using an H4 (for normalization) or a pan-acetylated
ndicate SEM.
Figure 7. NF-kB Inhibitor Suppresses Proliferation of ARID1A/PIK3CA Mutant Cells and Synergizes with Carboplatin
(A) The NF-kB inhibitor synergizes with carboplatin to suppress T80 (AM) cell proliferation. 33 105 of the indicated cells were plated on six-well plates. 1 day after
seeding, cells were treated with the indicated drugs and counted every 2 days (n = 3). Error bars indicate SEM.
(B) Synergistic effect of IKK-IIV and carboplatin in suppressing TOV-21G, but not ES-2, cell proliferation. Cells were assayed as in (A) (n = 3). Error bars
indicate SEM.
(C) Combined treatment of IKK-IIV and carboplatin inhibits TOV-21G tumor growth in a mouse xenograft model. 3 3 106 TOV-21G cells were subcutaneously
transplanted to 6-week-old female nude mice and housed until tumors reached a palpable size of 100 mm3. Mice were randomized into four groups for the
(legend continued on next page)
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(Grivennikov et al., 2009; Schwitalla et al., 2013; Takahashi et al.,
2010). Unlike these known NF-kB activation mechanisms,
OCCC uses a unique strategy to activate NF-kB. In OCCC, a
combination of two mutations that respectively derepress chro-
matin and activate a transcription factor contribute to cytokine
gene activation. It is important to note that upregulation of pro-
inflammatory cytokines in OCCC is achieved cell autonomously
by the two mutations without the involvement of any environ-
mental factors.
Potential Histone Acetyltransferases that Activate
Cytokines in OCCC
Our current study did not identify the responsible histone ace-
tyltransferases (HATs) cooperating with RelA in OCCC. So far,
two HATs have been implicated in NF-kB-mediated cytokine
transcription. The first is p300/CBP, which has been impli-
cated in cytokine induction in tumor necrosis factor (TNF-a)-
stimulated human umbilical vein endothelial cells (HUVEC)
and leukemia cells (Gerritsen et al., 1997; Perkins et al.,
1997). The second is Tip60, which has also been implicated
in cytokine induction in TNF-a-stimulated HepG2 cells (Kim
et al., 2012). To explore whether the two HATs are involved
in cytokine gene induction in OCCC, we treated both T80
(AM) and TOV-21G cells with an inhibitor of p300 (C636) or
Tip60 (Nu9056) or their combination. However, none of these
treatments reduced cytokine gene expression (M.K., unpub-
lished data). In addition, despite multiple attempts, we failed
to detect binding of p300 or Tip60 at cytokine gene promoters
in T80 (AM) cells. Thus, it is likely that HATs other than p300 or
Tip60 may be involved in cytokine gene induction in OCCC.
Identification of the responsible HAT may provide a target
for OCCC treatment.
NF-kB Inhibitor as a Potential Therapeutic Option for
ARID1A/PIK3CA Mutant Cancers
Our results show that NF-kB inhibition could selectively inhibit
the growth of ARID1A/PIK3CA mutant cells while leaving normal
cells or OCCC without these mutations unaffected. In addition,
we demonstrate both in cell culture and using a mouse model
that NF-kB inhibition potentiates the effect of carboplatin, which
is currently the first line of treatment for ovarian cancer but is not
effective for OCCC. Furthermore, cytokines upregulated in our
system are implicated in cancer-stromal interaction, which can
drive processes involved in cancer progression such as angio-
genesis (e.g., IL-8) (Waugh and Wilson, 2008) and metastasis
(e.g., CXCL1) (Acharyya et al., 2012). Therefore, we expect that
NF-kB inhibition could also benefit OCCC treatment by blocking
cancer progression. It would be informative to test this hypothe-indicated treatment, and tumor sizes were measured on the indicated days (n =
treatments is performed (either carboplatin only or IKK-IIV only, which resulted in
(D) Image of dissected tumors at the time of mouse sacrifice shown in (C). Scale
(E) Working model of how ARID1A/PIK3CA mutation induces cytokine express
complex recruited by ARID1A. At the same time, RelA is sequestered by IkB. (b) In
leading to histone acetylation. However, RelA is still sequestered by IkB. Thus, c
releases RelA from IkB. However, the presence of the Sin3A-HDAC complex limit
robustly induced, which contributes to cell proliferation and drug resistance.
**p < 0.01; ***p < 0.001. See also Figure S7.
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future. Additionally, the use of an NF-kB inhibitor would be a bet-
ter strategy than suppressing expression of a specific cytokine. It
is worth noting that a recent study revealed combined mutations
of ARID1A/PIK3CA in gastric adenocarcinoma (Zang et al.,
2012). It would be interesting to test if our findings in OCCC
can also be applied to this type of gastric cancer.
EXPERIMENTAL PROCEDURES
Mouse Xenograft Assay
All animal studies were performed in accordance with guidelines of the Institu-
tional Animal Care and Use Committee at Harvard Medical School. Six-week-
old female nude mice were purchased from Jackson Laboratory (stock no.
002019, homozygous for Foxn). 33 106 cells (mixed with 50%Matrigel, Corn-
ing) were subcutaneously injected into the right part of back skin. Tumor sizes
weremeasured using an electronic caliper. For treatment experiments, tumors
were grown until they reached palpable size of 100 mm3. Then, mice were
randomized into four groups and treated with saline, carboplatin only
(30 mg/kg, once per week), IKK-IIV only (25 mg/kg, twice per week), or a
combination by intraperitoneal injection.
RNA-Seq
RNA-seq libraries were made from poly(A)+ mRNA using NEBNext Ultra
Directional RNA Library Prep Kit for Illumina (New England Biolabs). Briefly,
mRNA was purified from 1 mg total RNA using NEBNext Poly(A) mRNA Mag-
netic Isolation Module (New England Biolabs) and fragmented by heating at
94C for 15 min. The fragmented RNA was reverse transcribed with random
primers. After second-strand DNA synthesis, the cDNA fragments were dA
tailed and adaptor ligated. PCR amplification was carried out to get sufficient
amount of libraries for sequencing. The libraries were sequenced on an Illu-
mina Hiseq2500 in single-end mode (Illumina). Sequencing reads were map-
ped to human genome hg19 using Tophat 2.0.13 (Trapnell et al., 2009). The
expression level of each gene was quantified with normalized FPKM (frag-
ments per kilobase of exon per million mapped fragments) using Cufflinks
2.2.1 (Trapnell et al., 2010). Gene set enrichment analysis was carried out using
GSEA v2.2.2 (Broad Institute) with expression data downloaded from GEO:
GSE6008 (Hendrix et al., 2006) and the set of upregulated genes in double-
mutant cells as gene set input. The default enrichment cutoff was used in
the analysis.
Dnase-I Hypersensitive Site Sequencing
DNase-seq libraries were prepared from 1 million cells following a published
protocol with minor modifications (He et al., 2014). The nuclei were digested
with DNase I (Roche) at 60 U/mL final concentration at 37C for 5 min. The re-
actions were stopped by adding stop buffer containing EDTA and proteinase
K. DNA was purified by phenyl-chloroform extraction and ethanol precipita-
tion. Small fragments around 150 bp were selected with SPRIselect (Beckman
Coulter). Sequencing libraries were prepared with NEBNext Ultra DNA Library
Prep Kit for Illumina (New England Biolabs). The libraries were sequenced on
an Illumina Hiseq2500 in single-end mode (Illumina). Sequencing reads were
mapped to human genome hg19 using Bowtie2 2.1.0 (Langmead and Salz-
berg, 2012). Differential DHSs with 3-fold difference were called using ChIPDiff
(Xu et al., 2008).5 per group). Statistical analysis comparing combined treatment and single
the same range of p values). Error bars indicate SEM.
bar, 5 cm.
ion. (a) In wild-type cells, cytokine genes are repressed by the Sin3A-HDAC
ARID1Amutant cells, the recruitment of the Sin3-HDAC complex is abolished,
ytokine induction is limited. (c) In PIK3CA active cells, the AKT-IKK2 pathway
s cytokine induction. (d) In the presence of both mutations, cytokine genes are
Statistical Analysis
All graphs were drawn using GraphPad Prism. Statistical analyses were per-
formed by paired Student’s t test (two tailed) comparing indicated pairs in
each figure.
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